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Background: Thyroxine (T4) hormone is synthesized by the thyroid gland and then
released into the systemic circulation where it binds to a number of proteins. Dysfunction
in T4 transport mechanisms has been demonstrated in multiple central nervous system
(CNS) diseases including Alzheimer’s disease. In the presence of different compounds
that inhibit potential T4 transport mechanisms, this study investigated the transfer of
T4 from cerebrospinal fluid (CSF) into Choroid Plexus (CP) and other brain tissues. The
compounds used were brefeldin A, low sodium artificial CSF (aCSF), BCH, phloretin, and
taurocholate (TA).
Methods: Radiolabeled T4 (
125I-T4) was perfused continuously into the CSF and was
assessed in several brain compartments with reference molecule 14C-mannitol and blue
dextran, using the in vivo ventriculo-cisternal perfusion (V-C) technique in the rabbit.
The aCSF containing the drug of interest was infused after 1 h of perfusion. Drugs were
applied independently to the aCSF after 1 h of control perfusion.
Results: Of interest, in presence of low sodium or BCH, the percentage recovery of
125I-T4, was increased compared to controls, with concomitant increase in T4 clearance.
Conversely, brefeldin A, phloretin, and TA did not exert any significant effect on the
recovery and clearance of 125I-T4 assessed in aCSF. On the other hand, the uptake of
125I-T4 into CP was raised by 18 fold compared to controls in the presence of brefeldin
A. In addition, low sodium, BCH, or phloretin alone, enhanced the uptake of 125I-T4
by almost 3-fold, whereas TA did not show any significant effect. Finally, the uptake
and distribution of 125I-T4 into other brain regions including ependymal region (ER) and
caudate putamen (CAP) were significantly higher than in controls.
Conclusion: Our study suggests the involvement of different mechanisms for the
transfer of 125I-T4 from CSF into CP and other brain regions. This transfer may implicate
sodium-dependent mechanisms, amino acid “L” system, or organic anion transporting
polypeptide (OATP).
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Zibara et al. Drugs affecting T4 transfer
Introduction
Thyroid hormone (TH) is essential for normal growth,
development of the central nervous system (CNS) (Goncalves
et al., 1990; Koibuchi, 2013), and neuronal regeneration in
adults after traumatic brain injury (TBI) (Francon et al., 1989).
Thyroxine hormone (T4) is synthesized by the thyroid gland
and then released into the systemic circulation where it binds
to a number of proteins such as albumin (ALB), transthyretin
(TTR), and thyroid binding globulin (TBG) (Baehr et al.,
2006). Hypothyroxinemia causes neurological deficit and mental
retardation in the fetus (Wei et al., 2013). In order for T4
to reach the CNS, it must first cross the brain barriers, i.e.,
endothelial cells of the blood-brain barrier (BBB) and epithelial
cells of the choroid plexus (CP) of blood-cerebrospinal fluid
barrier (BCSF-B). Dysfunction in T4 transport mechanisms has
been demonstrated in multiple diseases of the CNS. In fact, low
levels of free T4 in the CSF have been demonstrated in patients
with multiple sclerosis (Pieragostino et al., 2013) and Alzheimer’s
Disease (Johansson et al., 2013).
Despite the importance of studying the direction of T4
transport from blood into CNS, the underlying mechanisms
responsible for its entry from CSF into CP and brain, has not
been fully investigated. Few studies in mice revealed that T4
transport across BBB is primarily directed from brain to blood via
carrier-mediated mechanism (Banks et al., 1985). However, T4
injected directly into the CSF compartment in the rat penetrated
very poorly into the brain (Dratman et al., 1991; Blay et al.,
1993). In the rabbit, our laboratory have demonstrated that T4
transport from CSF into CP’s and other brain tissues is carrier-
mediated and dependent on the presence of T4 binding protein
TTR, synthesized by the CP’s (Kassem et al., 2006). Moreover, we
have also shown that in isolated perfused sheep CP, T4 transport
is partially dependent on sodium (Kassem et al., 2002).
Previous research has concentrated on studying the transport
direction of T4 from blood into the brain across the BBB
suggesting a role for organic anion transporting polypeptides
(OATP) such as OATP 1a4, 1c1, 2, 3, and 14, which are mainly
localized at the blood side of the BBB (Abe et al., 1998; Gao
and Meier, 2001; Mayerl et al., 2012; Do et al., 2013) and CP
(Gao et al., 1999; Gao and Meier, 2001; Mayerl et al., 2012).
On the other hand, others have demonstrated a role for OATP2
and multiple drug resistance 1 (MDR1) in the transport of 125I-
T4 at the basolateral side of the isolated perfused sheep CPs
(Preston and Segal, 1992). Furthermore, a potential role for P-
glycoprotein (P-gp) and OATP 1 & 3 was found in T4 transport
mechanism (Kassem et al., 2007). Finally, human OATP 1c1 has
been reported to have a high specificity for T4 and is considered
to play a critical role in its transport across the BBB (Jansen et al.,
2005; van der Deure et al., 2008). However, monocarboxylate
(MCT8) has been shown to transport T3 and T4 THs (Grijota-
Martínez et al., 2011).
Abbreviations: TH, thyroid hormones; T4, thyroxine; T3, triiodothyronine;
CSF, cerebrospinal fluid; CP, choroid plexus; V-C, ventriculo-cisternal; BBB,
blood-brain barrier; BCSF-B, blood-cerebrospinal fluid barrier; CNS, central
nervous system; BCH, β-2-aminobicyclo- (2,2.1)-heptane-2-carboxylic acid; TA,
taurocholate.
The aim of this study is to investigate the effect of
several cross-competing drugs on the transport of 125I-T4 from
CSF compartment into CP and the brain, using Ventriculo-
Cisternal (V-C) perfusion in the rabbit, and to potentially
characterize putative transporters contributing to this process.
The following drugs/conditions were used: brefeldin A (a blocker
of intracellular secretory proteins such as TTR, Klausner et al.,
1992), low sodium artificial CSF (aCSF), β-2-aminobicyclo-
(2,2.1)-heptane-2-carboxylic acid (BCH) (an amino acid analog
inhibitor of L-type transporters, Braun et al., 2011), phloretin (a
sugar analog), and taurocholate (TA) (an OATP inhibitor).
Materials and Methods
Animal Handling
All procedures were conducted according to the Home Office
legislation of the animal scientific procedures in compliance
with the guidelines of the current animal legislation Act, 1986
UK. This study was approved by the Institute Animal Care and
Utilization Committee of King’s College London.
Ventriculo-cisternal (V-C) Perfusion
This method has been previously described (Davson and Segal,
1970; Kassem et al., 2006, 2007). Briefly, 1.5–4 Kg New Zealand
white rabbits of either sex were anesthetized by the intravenous
injection of a mixture of sodium Pentobarbital (10mg/kg−1,
Sagatal, Sigma, UK) and Medetomidine hydrochloride
(0.5mg/kg−1, Domitor, Sigma, UK). Bilateral perfusion of
the ventricular system was carried out by placing two catheter
inflow needles into each lateral ventricle (Kassem et al., 2006).
The aCSF was infused into both ventricles by a pump (Harvard
22, UK) at a total rate of 60µl/min, containing 125I-labeled T4
(0.37 MBq/40ml), and the extracellular marker mannitol (0.148
MBq/40ml, New England Nuclear, UK). Artificial CSF contained
(in mmol/l): 153 Na+, 2.81 K+, 1.7Mg2+, 2.81 Ca2+, 131 Cl−,
1.7 SO2−4 , 1.48 PO
2−
4 , 27.4 HCO
−
3 , and 5.3 glucose. The solution
was then gassed with 95% O2 and 5% CO2. Low sodium aCSF
was used by replacing the NaCl and KCl in the perfusate with
choline chloride. The sodium content in the aCSF was made up
from NaHCO−3 , which contained ∼27mM Na. Blue dextran, a
large marker molecule of 2 ×106 kDa M.wt. (Sigma, UK) was
confined to the aCSF and used to determine the secretion rate
(Kf ) of the newly formed CSF (Davson and Segal, 1970; Kassem
et al., 2006). The outflow perfusate was collected continuously,
every 10min, from a single needle positioned in the cisterna
magna. Perfusion time lasted for 2 h, in all experiments.
Sampling of Brain Tissues and Isotopes Counting
This was performed as previously described (Kassem et al.,
2006, 2007). Briefly, rabbits were sacrificed, their brains rapidly
removed, and ventricles opened and flushed with 0.9% saline.
The brain hemispheres were split through the midline and cut
into series of coronal sections. The CP’s were removed, and
the ventricular ependymal region (ER) of the frontal cortex was
dissected, as 1mm thick layer (20 mg) from the area next to the
midline (Preston and Segal, 1992; Preston et al., 2005). The ER
was then gently peeled back from the rest of ventricular wall by
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a horizontal cut. The uptake of 125I-T4 into ER was compared
to tissue samples designated the subependymal region (SER),
located immediately below the dissected region (1mm thick,
20 mg). The rest of the brain was dissected into hippocampus
(HC) with or without ER (HC+ER or HC-ER), respectively. The
caudate putamen (CAP) was also processed.
Treatments
aCSF inflow and outflow samples (100µl in triplicate), and tissue
samples were dissolved in 0.5ml Solusol (National diagnostic,
UK). A total of 3.5ml of scintillation liquid was added (Ultima
Gold, Packard, UK) and samples were counted with LKBWallac-
1219 Beta liquid scintillation counter. Both 125I and 14C were
expressed as disintegration per minute (dpm).
Drugs
After control aCSF perfusion for 1 h, one of the following drugs
was separately added to the aCSF for another 1 h: brefeldin
A (5.0µg/ml) (Lei et al., 2003), low sodium (∼27mM), BCH
(5.0mM) (Preston et al., 2005), phloretin (100µM) (Deane and
Segal, 1979), or taurocholate (1.0mM) (Kitazawa et al., 2000).
Drugs were dissolved directly in aCSF. The effect of each drug was
compared to its own control experiment. The drugs were applied
to separate animals. The control for each experimental animal
was done before applying the specific drug, therefore; the effect
of each investigated drug was animal specific. Results represents
the average effect of each drug on n = 3–4 animals.
Expression of Results
Percent Recovery of 125I-T4 in aCSF
As previously published (Bradbury and Davson, 1964; Kassem
et al., 2006), the % of 125I-T4 remaining in outflow aCSF, in each
10min sample, was calculated from: % recovery = (Cout/Cin) ×
100, where theCout =
125I-T4 dpm.ml
−1,Cin =
125I -T4 dpm.ml
−1
inflow aCSF. The steady-state ratio of 125I-T4 in the recovered
aCSF was calculated from the mean value of % recovery derived
from the last four samples of perfusion fluid.
Clearance of 125I-T4 from aCSF
The rate of 125I-T4 loss from the aCSF during V-C perfusion was
expressed as clearance, defined as the volume (µl) of aCSF cleared
of 125I-T4 per minute. The equation employed has previously
been described (Kassem et al., 2006):
Clearance(µl.min−1) = Fin(Cin − RDCout)/(Cin + Cout)/2.
Where Cin is the
125I-T4 dpm.ml
−1 per unit volume of entering
aCSF; Cout is the
125I -T4 dpm.ml
−1 of emerging aCSF, Fin
is the rate of perfusion (µl. min−1), and RD is the ratio of
Dextran in steady-state of Cin/Cout, measured on a Unicam
spectrophotometer at 625 nm. The clearance of 125I-T4 from CSF
was corrected for CSF secretion rate (µl. min−1), every 10min
throughout each experiment.
Brain Uptake
At the end of 2 h of V-C perfusion, the regional brain uptake of
125I-T4 was expressed as follows:
RBr(ml.g
−1) = 100× tissue(dpm.g−1)/((Cin + Cout)
(dpm.ml−1)/2)
Where Cin and Cout are
125I-T4 in inflowing and outflowing
CSF from the ventricle, respectively. RBr was then corrected for
14C-mannitol content.
Statistics
All statistical calculations were performed using Microsoft Excel
and GraphPad Prism version 5.0 (GraphPad Inc). Results are
expressed as the mean ± SEM. Statistical comparisons were
performed using the Student’s t-test in order to determine
statistical significance at p < 0.05. Symbols indicate statistical
difference: (∗) p < 0.05, (∗∗) p < 0.001, (∗∗∗) p < 0.0001.
Results
Percentage Recovery and Clearance of 125I-T4 in
aCSF After 2 hr V-C Perfusion
Results have shown that recovery of blue dextran, used as
an indicator dye in this study, and the secretion rate of
newly secreted CSF (Figure 1) were consistent with previously
published data (Kassem et al., 2007). Indeed, whether or not
a drug was added, CSF secretion did not seem to change
significantly, after steady state had been reached (p > 0.05,
Table 1). The mean curves describing the achievement of steady
state during V-C perfusion with aCSF containing 125I-T4 and
blue dextran are shown in Figure 1. It’s worth noting that 14C-
mannitol was used as a reference extracellular marker.
The effect of brefeldin A, an intracellular secretory protein
blocker, or phloretin, a sugar analog, on recovery and clearance
of 125I-T4 in aCSF did not reach statistical significance (Table 1).
However, when low sodium aCSF was used, the recovery of 125I-
T4 in aCSF increased significantly from∼43 to∼62% (p < 0.01).
This increase in recovery rate was correlated with a significant
reduction in clearance by 47% (p < 0.001, Table 1), suggesting
sodium-dependent uptake of T4 from CSF into brain and CP.
Moreover, the application of BCH, an amino acid analog, also
caused a significant increase in the % recovery of 125I-T4 when
compared to controls (p < 0.05, Table 1), which also correlated
with a similar reduction in clearance by >50% (Table 1). On the
other hand, TA, an OATP inhibitor, did not have any effect on the
recovery or clearance of 125I-T4 in aCSF (Table 1).
Uptake into CP
Following the measurement of % recovery and clearance in
aCSF, and in order to examine the mechanism of T4 transport
from CSF, we have explored the uptake of 125I-T4 into CP.
The application of brefeldin A resulted in a significant 18-
fold increase of 125I-T4 uptake in CP compared to controls
(∼26ml.g−1 vs. 1.4ml.g−1; respectively, p < 0.001, Figure 2).
Moreover, in the presence of low sodium perfusate, there was a
significant 2.5 fold accumulation of 125I-T4 into CP as compared
to controls (∼3.5ml.g−1 vs. ∼1.4ml.g−1, p < 0.01, Figure 2).
Similarly, phloretin induced a significant 2.4 fold increase in the
uptake of 125I-T4 into CP (∼3.3ml.g
−1 vs.∼1.4ml.g−1, p < 0.01,
Figure 2). Furthermore, BCH significantly enhanced by 3-fold
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FIGURE 1 | A representative graph showing the recovery of blue dextran, 14C-mannitol and 125I-labeled T4 in outflow aCSF during 2h of V-C perfusion
in rabbits. Blue dextran was used as an indicator molecule for the newly secreted CSF under experimental conditions, whereas 14C-mannitol was used as an
extracellular marker. Data are presented as mean ± SEM of 13 samples taken at various time points, n = 5 rabbits for each condition.
TABLE 1 | Recovery and clearance of 125I-T4 from the aCSF in rabbits, in
the presence of various drug treatments.
125I-T4 Recovery (%)
125I-T4 Clearance (µl.min
−1)
Control 39.87 ± 3.68 43.42 ± 2.52
Brefeldin A (5µg/ml) 37.10 ± 2.12 46.12 ± 2.41
Low sodium 24.40 ± 2.20* 61.65 ± 2.04*
BCH (5.0mM) 27.78 ± 2.20* 53.02 ± 1.75*
Phloretin (100µM) 46.98 ± 11.82 41.33 ± 7.86
TA (1.0mM) 39.23 ± 3.17 44.12 ± 1.83
Values are given as mean ± SEM. * p < 0.05 (student’s t-test), in comparison to control.
n = 5 for control, n = 3 for each drug.
the uptake into CP (p < 0.05) compared to controls. On the other
hand, TA did not induce any change in 125I-T4 uptake (Figure 2).
Uptake into Other Brain Tissues
Since the uptake of 125I-T4 into CP was significantly raised,
we have examined its uptake into specific regions of the brain,
namely ER, SER, HC, and CAP. The application of brefeldin A
caused more than a 9-fold increase in 125I-T4 uptake throughout
various brain regions such as ER, SER, and the CAP. For example,
the uptake into ER and SER was increased by ∼10-fold as
compared to controls (p < 0.05, p < 0.001; respectively,
Table 2). Moreover, in presence of low sodium aCSF, the highest
brain uptake of 125I-T4 was found into the CAP (Table 2).
Brefeldin A treatment also significantly enhanced, but to a lesser
extent, the uptake into other brain tissues such as the ER of
the frontal cortex and HC (p < 0.05, Table 2). It is worth
noting that the latter tissues are very close to the ventricles
and have more direct surface contact with CSF. This indicates
that 125I-T4 increased uptake into those regions is largely due
to a sodium-dependent mechanism. Furthermore, BCH induced
the uptake of 125I-T4 into ER and CAP, which are close to the
perfusion site, indicating a role for “L” system in the uptake
FIGURE 2 | The uptake of 125I-labeled T4 into choroid plexus (CP) of
rabbits in the presence of brefeldin A, low sodium, BCH, phloretin, and
TA. Data is presented as the mean and error bars represent SEM. Asterisks
indicate statistical significance using student’s t-test between treatment and
control for the indicated brain region, *indicates p < 0.05, **p < 0.01,
***p < 0.001. n = 5 for control, n = 3 for each drug.
mechanism. Phloretin treatment also caused a similar increase
in the 125I-T4 uptake into ER and CAP (Table 2), suggesting
a phloretin-dependent mechanism as well. Indeed, phloretin
treatment represents the second largest effect on 125I-T4 uptake
into brain tissue amongst the drugs tested in this study after
that obtained by brefeldin A. Finally, TA treatment resulted in a
significant increase in the uptake of 125I-T4 into the ER and CAP
brain regions as compared to controls (Table 2).
Discussion
Our previous studies have shown that T4 transfer from the CSF
compartment into lateral CPs and the surrounding brain regions
was dependent on TTR and P-gp (Kassem et al., 2006, 2007).
The present study reveals that T4 transport is affected by the
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TABLE 2 | Effects of various drug treatments on the uptake of 125I-T4 (ml.g
−1) in various brain tissues of rabbits.
Treatment/condition Uptake of 125I-T4 (ml.g
−1) in each brain region
ER SER CAP HC+ER HC-ER
Control 0.10± 0.03 0.01± 0.002 0.1±0.02 0.04±0.01 0.02±0.01
Brefeldin A 1.03± 0.10* 0.12± 0.02*** 1.0±0.30** 0.20±0.04** 0.20±0.04*
Low sodium 0.30± 0.12** 0.02± 0.01 1.10±0.10*** 0.10±0.02* 0.04±0.01
BCH 0.32± 0.20* 0.01± 0.001 0.21±0.04* 0.10±0.02 0.04±0.02
Phloretin 0.40± 0.10** 0.03± 0.01 0.40±0.14** 0.10±0.04 0.03±0.01
Taurocholate 0.21± 0.04* 0.13± 0.03 0.20±0.10* 0.10±0.02 0.01±0.01
ER, ependymal region, SER, subependymal region, CAP, caudate putamen, HC-ER, hippocampus with ER being removed. HC+ER = HC plus ER. Values are given as mean ± SEM,
n = 3-5. *p < 0.05, **p < 0.01, ***p < 0.001 (student’s t-test).
presence of several conditions/drug inhibitors such as brefeldin
A, low sodium, BCH, or phloretin and TA. The following lines
of evidence support the above statement: (Baehr et al., 2006)
the percentage recovery of 125I-T4, in presence of low sodium
or BCH was increased, in comparison to control, compatible
with a significant increase in T4 clearance, (Goncalves et al.,
1990) the uptake of 125I-T4 into CP was significantly increased
in the presence of brefeldin A, low sodium, BCH or phloretin,
(Koibuchi, 2013) the uptake of 125I-T4 into other brain regions,
especially ER and CAP, was significantly increased in presence of
all drugs as compared to controls, (Francon et al., 1989) TA did
not have any effect on the uptake of 125I-T4 into CP, but enhanced
the uptake into ER and CAP.
Consistent with previously published studies, and using the
V-C perfusion method, our data revealed that the baseline
characteristics of CSF secretion and blue dextran recovery
remained stable (Davson and Segal, 1970; Kassem et al., 2007).
On the other hand, treatment with brefeldin A, a fungal toxin that
disconnects the secretory, recycling, and degradation pathways
for membrane proteins (Farwell et al., 1996), resulted into a
considerable 18-fold accumulation of 125I-T4 uptake into the
CP. Moreover, it caused a large distribution of 125I-T4 into the
surrounding brain regions such as ER, SER, and HC+ER, when
compared to controls. However, brefeldin A treatment had little
effect on the % recovery of 125I-T4. These data suggest that a
membrane transport protein system for T4 is present at the apical
side of the CP tissue and on the CSF side of the ER tissue.
Therefore, this transport mechanism is involved in the 125I-T4
uptake mechanism. Although there was no direct measurement
for the effect of brefeldin A treatment on the uptake of T4 into
CP in the presence of TTR, a role for this protein could also
be contributing to this transport mechanism. In fact, previous
research has demonstrated that incubation of cultured cells with
brefeldin A has prevented active secretion of TTR into the culture
medium (Patel et al., 2012).
The transport of 125I-T4 from CSF to CP and other regions
of the brain was demonstrated to be sodium-dependent. Indeed,
not only did the low sodium perfusate significantly inhibit the
clearance from CSF, but it also increased 125I-T4 availability
in the CSF compartment, and subsequently resulted into a
3 fold accumulation of 125I-T4 uptake into CPs. Our data
complement our previous findings which have demonstrated a
sodium-dependent mechanism responsible for T4 transport on
the apical side of the isolated perfused CP of sheep (Dickson
et al., 1987). Previous studies have also shown that CP is an
important eﬄux pathway for T4 (Dickson et al., 1987; Kassem
et al., 2001), and other compounds (Strazielle and Ghersi-Egea,
1999). The increase in T4 uptake in the CP in this study could be
due to the inhibitory effect of low sodium on sodium-dependent
transporters present at the blood side of the CP. In addition,
the low extracellular sodium aCSF may also have an inhibitory
effect on Na+/H+ exchange with blood side of both BBB and
B-CSF barriers. Therefore, a reduction in 125I-T4 eﬄux across
the BBB could subsequently increase its retention within the
CSF ventricular compartment. For instance, the increase in 125I-
T4 uptake was also observed in CAP which suggests a similar
mechanism. Moreover, in hepatic cells, uptake of TH has been
induced by the Na+/TA transporting polypeptide (NTCP) and
OATP1 (Friesema et al., 1999), which are both found to be
expressed at low levels in the rat CP (Choudhuri et al., 2003).
Furthermore, the sodium-dependent mechanism of TH has been
demonstrated in rat skeletal muscle (Centanni and Robbins,
1987), human glioma cells (Goncalves et al., 1990), rat glial
cells (Francon et al., 1989), astrocytes (Beslin et al., 1995), and
cerebrocortical neurons (Chantoux et al., 1995). Finally, as a
consequence of low sodium effect in this study and results of
another study (Kassem et al., 2006), the abundant presence of
125I-T4in CSF suggests a partial rapid diffusion of
125I-T4 into
tissue that is driven by a bulk flow of CSF and receptor-mediated
endocytosis (Kassem et al., 2006).
Following the addition of BCH, an amino acid analog which
functions as a substrate for “L” system transporter (Christensen
et al., 1989; Stewart et al., 1989), significant reduction in the
clearance of 125I-T4 from CSF was observed. This indicates that
125I-T4 was inhibited from leaving the perfusate and competed
with the “L” amino acid transport system. The high accumulation
of 125I-T4 uptakeinto CPs, following BCH application, is
indicative of an inhibition of the “L” system localized at the
basolateral side of the CPs (Christensen et al., 1989; Stewart
et al., 1989). It is worth noting that another study employing
BCH, using isolated perfused CP of the sheep, has reported a
slight increase in the 125I-T3 eﬄux from CSF to the blood and
a significant reduction in the uptake at the blood side (Preston
and Segal, 1992). This inhibition of “L” system transport by
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BCH has been found to contribute significantly to the transport
of iodothyronine (T3 and T4) in a human carcinoma cell line
(Powell et al., 2000; Hennemann et al., 2001) and brain astrocytes
(Braun et al., 2011). Our data on CPs is consistent with others
who demonstrated that “L-type” amino acid transporters (LATs)
facilitate TH uptake in xenopus oocytes (Jansen et al., 2005).
Furthermore, the transport of T3 and T4 appeared to be mediated
by L and T amino acid TH transporters in mouse neuroblastoma
cultured cells (Hennemann et al., 2001). This transport was
decreased by BCH, confirming the involvement of the amino
acid “L” system (Lakshmanan et al., 1990). On the other hand,
ER appeared to have been affected by the reduction in 125I-
T4 clearance from CSF, as a result of “L” system inhibition at
the levels of both CPs and BBB. Our data suggests that the “L”
system is expressed in ER and CAP and that the T4 uptake
mechanism into these brain regions studied is BCH-dependent.
This is consistent with previous research which indicated that
circulating T4 preferentially crosses the BBB through several
amino acid transporters (Koibuchi, 2013). Our data on BCH
in 125I-T4 transport from CSF into CPs and the brain, across
the “L” system, has not been previously reported and may be of
physiological importance.
Phloretin treatment resulted in a 3-fold increase in the uptake
of 125I-T4 into CPs, ER and CAP compared to controls. It is well
known that this drug has an inhibitory effect on protein binding
(McLeese and Eales, 1996), GLUT1 glucose transporter, and the
iodothyronine-5′-deiodinase (Movius et al., 1989; Morreale de
Escobar et al., 1994). Our data is in agreement with previous
studies in the field, which have demonstrated the inhibitory effect
of phloretin on the glucose flux from CSF to blood using the
isolated perfused CPs of the sheep (Deane and Segal, 1979). It
is worth noting that since phloretin binds to the mammalian
hexose/sugar transporter (Deane and Segal, 1979), this would
involve the energy dependent P-gp. Indeed, the latter has been
proven to be involved in the transfer of 125I-T4 between the CSF,
CP, and brain (Kassem et al., 2007). In addition, since there is
structural similarities between phloretin and T3, more
125I-T4
can diffuse into the cell by lipid partitioning. In fact, phloretin
is known to have an inhibitory effect on glucose transporter
(GLUT) in human cancer cells (Wu et al., 2009), and therefore
may simply compete with sugar transporters or other unknown
T4 transporters. Previous studies on rat hepatocarcinoma have
reported an inhibitory effect of phloretin on GLUT1 and
GLUT2 activity localized on apical and basolateral sides of
the CP epithelial cells respectively (Rodríguez-Enríquez et al.,
2009; Balmaceda-Aguilera et al., 2012). In addition, it has been
proposed that phloretin has competitively inhibited T3 uptake
into human hepatocarcinoma cultured cells in a dose-dependent
manner (Movius et al., 1989). In contrast, phloretin was shown to
reduce the 125I-T4 uptake in isolated trout hepatocytes (Riley and
Eales, 1993). Other studies have proven that GLUT1 is localized
at the basolateral side of cultured epithelial CP cells (Villalobos
et al., 1997) and on both sides of capillary endothelial cells of the
BBB (Stewart et al., 1994), hence this transporter may prevent the
removal of 125I-T4 from CSF/brain to the blood. Therefore, it can
be hypothesized that the retention of 125I-T4 by the brain can be
the consequence of a decrease in the eﬄux of 125I-T4 from the
CSF and brain to blood across the brain barriers.
In the presence of TA, the uptake of 125I-T4 into some brain
tissues, such as ER and CAP, was increased. This suggests an
interaction between TA and OATP 1a4 since TA was proven to
be an OATP 1a4 substrate and sensitive transporter (Do et al.,
2013). This agrees with a previous study which demonstrated that
OATP2 and OATP3 mediate TH transport when their mRNA is
injected into xenopus oocytes (Abe et al., 2002). Furthermore,
our data suggests that OATP2 of the abluminal membrane is
involved in T4 accumulation into those tissues since OATP2 has
been identified on the luminal and abluminal membrane of the
rat brain capillary endothelial cells (Gao et al., 1999). However,
we cannot exclude a role for OATP2 present on the luminal side.
Finally, the mediation of T4 uptake by organic anion as well as
MCT8 was also found in human hepatocarcinoma cells (Ritchie
and Taylor, 2010). MCT8, also known as solute carrier (Slc16a2),
has been reported to be involved in the uptakemechanism of 125I-
T4 into the brain from the circulation (Kogai et al., 2010; Braun
et al., 2011; Horn et al., 2013).
The decrease in TTR synthesis at the blood-CSF-barrier (CP)
has been previously shown in aging sheep (Chen et al., 2006).
These changes suggested reduced capacity of CP to maintain
CSF T4 homeostasis, and could also reduce chelation of beta-
amyloid, which may result in an added risk for Alzheimer’s
disease in patients experiencing similar changes in TTR synthesis.
In addition, albumin and TTR have been shown to inhibit T4
uptake from CSF into isolated sheep brain tissue in a dose-
dependent manner (Chen et al., 2005). Therefore, those two
proteins (albumin and TTR) prevent the loss of T4 from CSF to
blood, and enhances the redistribution of T4 around the brain.
The increase in T4 recovery and clearance in presence of
low sodium or BCH, was due respectively to the inhibition
of Na+/K+-ATPase or L-type amino acid transporters. Both of
these transporters are localized at the basolateral side of the CP,
which was reflected by the accumulation of T4 in the CP. The
results imply that T4 uptake into the CP and brain is largely
dependent on the sodium gradient. We suggest that T4 transport
into the brain and CP is dependent on the concentration
of extracellular sodium and/or OATP2 transport mechanisms.
Although, treatment with drugs such as Brefeldin A, Phloretin,
and TA resulted in a variable increase in T4 uptake into CP, they
failed to cause a significant change in T4 recovery and clearance
from CSF. This could be due to either poor penetration of the
drugs into the cells, or that the used concentrations were not at
optimal levels to produce an effect at the BBB.
In conclusion, the uptake of 125I-T4 from CSF into CPs
suggests the involvement of at least two transport mechanisms
among the following: sodium-dependent mechanism, amino
acid “L-type” transport system, or OATP transporters. Since the
uptake into other brain regions was lower than that obtained in
the CPs, we hypothesize that the major eﬄux pathway of 125I-T4
from CSF into the brain tissue toward the blood occurs across the
blood-CSF barrier, which could exclude any potential role for the
BBB in the process.
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